Overview
Study of Ivacaftor in Cystic Fibrosis Subjects 2 Through 5 Years of Age With a CFTR Gating Mutation
Status:
Completed
Completed
Trial end date:
2014-03-01
2014-03-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD), of ivacaftor in children with cystic fibrosis (CF) who are 2 through 5 years of age and have a CF Transmembrane Conductance Regulator (CFTR) gating mutation in at least 1 allele. Part A is designed to evaluate the safety and PK of multiple-dose administration of ivacaftor in participants 2 through 5 years of age and to confirm the doses for Part B. Part B is designed to evaluate the safety, PK, PD, and efficacy of ivacaftor in participants 2 through 5 years of age.Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Vertex Pharmaceuticals IncorporatedCollaborators:
Cystic Fibrosis Foundation
Cystic Fibrosis Foundation TherapeuticsTreatments:
Ivacaftor
Criteria
Inclusion Criteria:- Male or female with confirmed diagnosis of CF
- Must have a CFTR gating mutation in at least 1 allele
- Aged 2 through 5 years at screening and Day 1
- Weight >= 8 kg at screening and Day 1
- Hematology, serum chemistry, coagulation, and vital signs results at screening with no
clinically significant abnormalities that would interfere with the study assessments,
as judged by the investigator
Exclusion Criteria:
- History of any illness or condition that, in the opinion of the investigator, might
confound the results of the study or pose an additional risk in administering study
drug to the participant
- An acute upper or lower respiratory infection, or pulmonary exacerbation, or changes
in therapy for pulmonary disease within 4 weeks before Day 1
- Abnormal liver function, at screening
- History of solid organ or hematological transplantation
- Use of any moderate or strong inducers or inhibitors of cytochrome P450 (CYP) 3A
within 2 weeks before Day 1
- Participation in a clinical study involving administration of either an
investigational or a marketed drug within 30 days or 5 terminal half-lives before
screening